It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sepsis is the leading cause of acute kidney injury (AKI) and lung injury worldwide. Despite therapeutic advances, sepsis continues to be associated with high mortality. Because Brazilian green propolis (GP) has promising anti-inflammatory, antioxidant, and immunomodulatory properties, we hypothesized that it would protect kidneys and lungs in rats induced to sepsis by cecal ligation and puncture (CLP). Male Wistar rats were divided into groups—control (sham-operated); CLP (CLP only); and CLP + GP (CLP and treatment with GP at 6 h thereafter)—all receiving volume expansion and antibiotic therapy at 6 h after the procedures. By 24 h after the procedures, treatment with GP improved survival, attenuated sepsis-induced AKI, and restored renal tubular function. Whole-blood levels of reduced glutathione were higher in the CLP + GP group. Sepsis upregulated the Toll-like receptor 4/nuclear factor-kappa B axis in lung and renal tissues, as well as increasing inflammatory cytokine levels and macrophage infiltration; all of those effects were attenuated by GP. Treatment with GP decreased the numbers of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive cells in renal and lung tissue, as well as protecting the morphology of the renal mitochondria. Our data open the prospect for clinical trials of the use of GP in sepsis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of São Paulo School of Medicine, Laboratory of Basic Science in Renal Diseases, Division of Nephrology, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
2 University of São Paulo School of Medicine, Laboratory of Basic Science in Renal Diseases, Division of Nephrology, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); University of Goiás, Catalão, Brazil (GRID:grid.11899.38)
3 University of São Paulo School of Medicine, Laboratory of Cellular, Genetic, and Molecular Nephrology, Division of Nephrology, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
4 Apis Flora Industrial e Comercial Ltda, Laboratório de Pesquisa, Desenvolvimento e Inovação (P, D & I), Ribeirão Preto, Brazil (GRID:grid.456434.4)
5 Federal University of Alagoas, School of Medicine, Maceió, Brazil (GRID:grid.411179.b) (ISNI:0000 0001 2154 120X)